AVITA Medical, Inc. (RCEL)
NASDAQ: RCEL · Real-Time Price · USD
11.17
+0.87 (8.45%)
Nov 4, 2024, 4:00 PM EST - Market closed
Company Description
AVITA Medical, Inc., together with its subsidiaries, operates as a regenerative medicine company in the United States and internationally.
The company’s lead product is the RECELL System, a cell harvesting device used for the treatment of thermal burn wounds, full-thickness skin defects, and repigmentation of stable depigmented vitiligo lesions.
It develops RECELL GO to control the manual process of disaggregation, filtration, and soak time. The company was formerly known as AVITA Therapeutics, Inc. AVITA Medical, Inc. was incorporated in 2020 and is headquartered in Valencia, California.
AVITA Medical, Inc.
| Country | United States |
| Founded | 2020 |
| Industry | Medical Devices |
| Sector | Healthcare |
| Employees | 207 |
| CEO | James Corbett |
Contact Details
Address: 28159 Avenue Stanford, Suite 220 Valencia, California 91355 United States | |
| Phone | 661 367 9170 |
| Website | avitamedical.com |
Stock Details
| Ticker Symbol | RCEL |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001762303 |
| CUSIP Number | 05380C102 |
| ISIN Number | US05380C1027 |
| Employer ID | 20-2578762 |
| SIC Code | 3841 |
Key Executives
| Name | Position |
|---|---|
| James M. Corbett | Chief Executive Officer, President and Executive Director |
| David O'Toole | Chief Financial Officer |
| David Fencil | Senior Vice President of Global Operations |
| Dr. Katie Bush Ph.D. | Senior Vice President of Scientific and Medical Affairs |
| Jessica Ekeberg | Investor Relations Executive |
| Nicole Linda Kelsey | Chief Legal and Compliance Officer and Corporate Secretary |
| Debbie Garner | Senior Vice President of Global Marketing and Strategy |
| Rob Hall | Senior Vice President of Human Resources |
| Dr. Niraj Doshi J.D., P.M.P., Ph.D. | Senior Vice President of Product Development and Program Management |
| Ron Lagerquist | Senior Vice President of Quality Assurance and Regulatory Affairs |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Aug 8, 2024 | S-8 | Securities to be offered to employees in employee benefit plans |
| Aug 8, 2024 | 10-Q | Quarterly Report |
| Aug 8, 2024 | 8-K | Current Report |
| Jul 31, 2024 | 8-K | Current Report |
| Jul 1, 2024 | 8-K | Current Report |
| Jun 6, 2024 | 8-K | Current Report |
| May 30, 2024 | 8-K | Current Report |
| May 13, 2024 | 10-Q | Quarterly Report |
| May 13, 2024 | 8-K | Current Report |
| Apr 23, 2024 | DEF 14A | Other definitive proxy statements |